Camrelizumab
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Resectable Esophageal Squamous Cell Carcinoma
Conditions
Resectable Esophageal Squamous Cell Carcinoma
Trial Timeline
Sep 1, 2021 → Dec 31, 2030
NCT ID
NCT05043688About Camrelizumab
Camrelizumab is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Resectable Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05043688. Target conditions include Resectable Esophageal Squamous Cell Carcinoma.
What happened to similar drugs?
1 of 20 similar drugs in Resectable Esophageal Squamous Cell Carcinoma were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05547737 | Pre-clinical | UNKNOWN |
| NCT05093140 | Phase 2 | UNKNOWN |
| NCT05043688 | Phase 3 | Recruiting |
| NCT04805736 | Phase 2 | Completed |
| NCT05099848 | Phase 2 | UNKNOWN |
| NCT03912857 | Phase 2 | UNKNOWN |
| NCT02742935 | Phase 1 | Completed |
Competing Products
20 competing products in Resectable Esophageal Squamous Cell Carcinoma